Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) delivers transformative intelligence through market-leading platforms like Web of Science™ and Cortellis™, powering innovation across academia, intellectual property, and life sciences. This news hub provides investors and professionals with direct access to official announcements shaping global research and commercialization efforts.
Track critical updates including quarterly earnings disclosures, strategic partnerships, product launches, and regulatory filings. Our curated feed ensures timely access to press releases about AI-driven analytics advancements, IP portfolio developments, and expansions in pharmaceutical intelligence solutions.
Key content categories include financial performance reports, acquisition announcements, leadership updates, and innovations in real-world data applications. Bookmark this page to monitor Clarivate's progress in converting transactional revenues to high-margin subscriptions while maintaining its position as a critical enabler of R&D workflows.
Clarivate reported first-quarter 2024 results with revenues of $621.2 million, a 1.3% decrease. The net loss attributable to ordinary shares was $93.8 million. Adjusted net income decreased by 20.9% to $103.5 million. The company reaffirmed its outlook for 2024.
Clarivate Plc (NYSE: CLVT) has introduced Epidemiology Intelligence™, a new solution that provides biopharma companies with epidemiology, incidence, and prevalence data, along with claims-based population insights, to enhance market sizing and patient population analysis. The tool aims to address limitations in traditional research methods, offering unique insights for accurate forecasting and identification of niche populations. The launch signifies Clarivate's commitment to delivering comprehensive solutions to the life sciences and healthcare industries.
Clarivate Plc (NYSE:CLVT) has launched the enhanced Cortellis CMC Intelligence solution with a post-approval variations module. This update allows pharmaceutical companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics. The module covers regulatory changes across 64 countries, reducing tracking time and increasing submission rates. Cortellis CMC Intelligence aims to simplify CMC regulatory dossier submissions, automate monitoring through alerts, and offer comprehensive lifecycle information for drugs and biologics.
Clarivate Plc declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares, payable on June 3, 2024. Each Preferred Share will convert into ordinary shares based on the VWAP of Clarivate's shares. The conversion rate depends on the VWAP value, with specific ratios based on price levels. Shareholders of record on May 15, 2024, will receive the dividend.
BioWorld by Clarivate explores the future of CAR T therapy in mainland China, focusing on the rapid pipeline growth, partnerships, clinical trials, and patient access challenges in cancer treatment. The report highlights the exponential growth of China's CAR T market, the blooming CAR T pipelines, and the difficulties in providing access to CAR T therapies due to high costs and reimbursement challenges.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
